Mustang Bio (DB:2W60) - Prezzo delle azioni, notizie e analisi

2W60 Panoramica delle azioni

A clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Maggiori dettagli

2W60 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 2.4% all'anno per i prossimi 3 anni

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Le azioni sono altamente illiquide

Non ha una capitalizzazione di mercato significativa ( €50M )

+ 2 più rischi

Mustang Bio, Inc. Concorrenti

4SC

DB:VSC

€48.2m

2invest

XTRA:2INV

€63.8m

Medigene

XTRA:MDG1

€22.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Mustang Bio
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$4.84
Massimo di 52 settimane	US$11.06
Minimo di 52 settimane	US$4.19
Beta	1.85
1Variazione di 1 mese	0%
Variazione a 3 mesi	-3.53%
Variazione di 1 anno	-40.63%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-88.23%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	2W60	DE Biotechs	DE Mercato
7D	0%	-0.7%	-0.02%
1Y	-40.6%	-17.2%	8.2%

Ritorno vs Industria: 2W60 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -17.2 % nell'ultimo anno.

Rendimento vs Mercato: 2W60 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.2 % nell'ultimo anno.

Volatilità dei prezzi

Is 2W60's price volatile compared to industry and market?
2W60 volatility
2W60 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Prezzo delle azioni stabile: 2W60 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 2W60 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	113	Manny Litchman	www.mustangbio.com

Mustang Bio, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Mustang Bio con la sua capitalizzazione di mercato?
2W60 statistiche fondamentali
Capitalizzazione di mercato	€46.25m
Guadagni(TTM)	-€68.20m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.7x

Rapporto P/E

2W60 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2W60 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$74.42m
Guadagni	-US$74.42m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-9.16
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	92.5%

Come si è comportato 2W60 nel lungo periodo?

Vedi performance storica e confronto

2W60 Panoramica delle azioni

Analisi del rischio

Mustang Bio, Inc. Concorrenti

DB:VSC

€48.2m

XTRA:2INV

€63.8m

XTRA:MDG1

€22.6m

XTRA:HPHA

€103.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Recent updates

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $4.398333 million.

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

President recently bought €211k worth of stock

Mustang Bio, Inc. Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc.(NasdaqGM:MBIO) dropped from Russell 2500 Growth Index

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

Key Executive recently sold €56k worth of stock